ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.59
1.05%
US Tech 100
20,333.60
1.61%
S&P 500
5,954.50
1.59%
US Dollar vs CAD
1.44675
0.00%
Bitcoin
84,958.01
0.70%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Arcturus Therapeutics Holdings Inc (ARCT) Share Price

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc (ARCT)

NASDAQ
16.79
0.73
(4.55%)
Closed February 28 3:00PM
Delayed by 15 minutes
16.79
-0.01
(-0.06%)
After Hours: 5:31PM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
16.79
Bid
16.30
Ask
16.79
Volume
388,095
15.41 Day's Range 16.90
14.30 52 Week Range 45.00
Market Cap
454.797M
Previous Close
16.06
Open
16.00
Last Trade
1
@
16.21
Last Trade Time
Financial Volume
US$ 6,260,979
VWAP
16.1326
Average Volume (3m)
408,676
Shares Outstanding
27,087,359
Dividend Yield
-
PE Ratio
-15.31
Earnings Per Share (EPS)
-1.1
Revenue
166.8M
Net Profit
-29.73M

About Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of... Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
arcturusrx.com
Headquarters
San Diego, California, USA
Founded
-
Arcturus Therapeutics Holdings Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ARCT. The last closing price for Arcturus Therapeutics was US$16.06. Over the last year, Arcturus Therapeutics shares have traded in a share price range of US$ 14.30 to US$ 45.00.

Arcturus Therapeutics currently has 27,087,359 shares outstanding. The market capitalization of Arcturus Therapeutics is US$435.02 million. Arcturus Therapeutics has a price to earnings ratio (PE ratio) of -15.31.

Ask ADVFN Intelligence (AI)

ARCT Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
December 18 2024
ARCT (4.55%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.45-2.6102088167117.2417.8615.8839941016.6423609CS
4-0.82-4.6564452015917.6119.1715.3442334616.82950141CS
12-1.26-6.9806094182818.0521.2614.340867617.06680641CS
26-3.68-17.977528089920.4725.8814.339724818.48361136CS
52-25.57-60.363550519442.364514.346731024.57123456CS
156-6.63-28.309137489323.424511.748575623.21436953CS
2603.7929.153846153813129.718.5162200737.6833091CS

ARCT - Frequently Asked Questions (FAQ)

What is the current Arcturus Therapeutics share price?
The current share price of Arcturus Therapeutics is US$ 16.79
How many Arcturus Therapeutics shares are in issue?
Arcturus Therapeutics has 27,087,359 shares in issue
What is the market cap of Arcturus Therapeutics?
The market capitalisation of Arcturus Therapeutics is USD 435.02M
What is the 1 year trading range for Arcturus Therapeutics share price?
Arcturus Therapeutics has traded in the range of US$ 14.30 to US$ 45.00 during the past year
What is the PE ratio of Arcturus Therapeutics?
The price to earnings ratio of Arcturus Therapeutics is -15.31
What is the cash to sales ratio of Arcturus Therapeutics?
The cash to sales ratio of Arcturus Therapeutics is 2.73
What is the reporting currency for Arcturus Therapeutics?
Arcturus Therapeutics reports financial results in USD
What is the latest annual turnover for Arcturus Therapeutics?
The latest annual turnover of Arcturus Therapeutics is USD 166.8M
What is the latest annual profit for Arcturus Therapeutics?
The latest annual profit of Arcturus Therapeutics is USD -29.73M
What is the registered address of Arcturus Therapeutics?
The registered address for Arcturus Therapeutics is 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO, CALIFORNIA, 92121
What is the Arcturus Therapeutics website address?
The website address for Arcturus Therapeutics is arcturusrx.com
Which industry sector does Arcturus Therapeutics operate in?
Arcturus Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
STAKSTAK Inc
US$ 3.97
(156.13%)
173.35k
ORGOOrganogenesis Holdings Inc
US$ 6.21
(102.28%)
58.69M
TRNRInteractive Strength Inc
US$ 2.57
(67.97%)
192.48M
PMAXPowell Max Ltd
US$ 0.511
(43.54%)
136.35M
ARBBARB IOT Group Ltd
US$ 0.6635
(38.23%)
58.86M
NVNINVNI Group Ltd
US$ 0.99
(-50.50%)
72.28M
SPGCSacks Parente Golf Inc
US$ 0.2085
(-48.65%)
57.4M
ADGMAdagio Medical Holdings Inc
US$ 0.8081
(-47.53%)
756.64k
PRAXPraxis Precision Medicines Inc
US$ 38.60
(-40.64%)
3.17M
SAGSAG Holdings Ltd
US$ 1.19
(-38.97%)
788.89k
NVDANVIDIA Corporation
US$ 124.92
(3.97%)
389.46M
TRNRInteractive Strength Inc
US$ 2.57
(67.97%)
193.54M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 13.44
(7.78%)
154.44M
PMAXPowell Max Ltd
US$ 0.511
(43.54%)
137.17M
LCIDLucid Group Inc
US$ 2.22
(-0.45%)
136.17M

ARCT Discussion

View Posts
Monksdream Monksdream 5 months ago
ARCT a buy again
👍️0
Monksdream Monksdream 7 months ago
That awful Cathie Wood has been a recent buyer
👍️0
Monksdream Monksdream 7 months ago
ARCT 10Q due AUGUST5
👍️0
Monksdream Monksdream 12 months ago
ARCT 10Q due March 7
👍️0
Monksdream Monksdream 1 year ago
ARCT new 52 week high
👍️0
Monksdream Monksdream 2 years ago
Arcturus Therapeutics (ARCT)
icon-fall
19%
Shares of Arcturus Therapeutics traded down ~19% on Tuesday after the company announced4 lower-than-expected revenue and earnings for the second quarter. According to management, revenue declined in response to the termination of two agreements, one with Vinbiocare and another with the Israeli Ministry of Health. Arcturus Therapeutics develops mRNA-based vaccines and therapeutics for the treatment of infectious and rare genetic diseases.
👍️0
Monksdream Monksdream 2 years ago
Arcturus Therapeutics Holdings Inc NASDAQ: ARCT

GoSymbol lookup
Health Care : Biotechnology | Small Cap GrowthCompany profile
Arcturus Therapeutics Holdings Inc. is a global late-stage clinical messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform







and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.
Arcturus Therapeutics (ARCT)
icon-rise-1
15%
Shares of Arcturus Therapeutics traded up ~15% on Friday after the company’s vaccine, ARCT-154, demonstrated6 an improvement in immunogenicity—43% more neutralizing antibodies at a lower dose than Comirnaty®. Arcturus Therapeutics develops mRNA-based vaccines and therapeutics for the treatment of infectious and rare genetic diseases.

Arcturus Therapeutics (ARCT)
icon-rise-1
15%
Shares of Arcturus Therapeutics traded up ~15% on Friday after the company’s vaccine, ARCT-154, demonstrated6 an improvement in immunogenicity—43% more neutralizing antibodies at a lower dose than Comirnaty®. Arcturus Therapeutics develops mRNA-based vaccines and therapeutics for the treatment of infectious and rare genetic diseases.
Arcturus Therapeutics (ARCT)
icon-rise-1
15%
Shares of Arcturus Therapeutics traded up ~15% on Friday after the company’s vaccine, ARCT-154, demonstrated6 an improvement in immunogenicity—43% more neutralizing antibodies at a lower dose than Comirnaty®. Arcturus Therapeutics develops mRNA-based vaccines and therapeutics for the treatment of infectious and rare genetic diseases.
👍️0
IOUBLOKE1 IOUBLOKE1 3 years ago
Silence is golden ARC
👍️0
IOUBLOKE1 IOUBLOKE1 3 years ago
Wow big after hours green buy
👍️0
IOUBLOKE1 IOUBLOKE1 3 years ago
Spike delivers in Canada 400 million does
👍️0
make it happen make it happen 4 years ago
http://archive.fast-edgar.com/20210812/A2Z2M22C3Z2232K222JN2CZ272FUV22SE232/ another company that directs them selling out potentially seems like a big negative along with many downgrades over $20.00 less than current PPS
👍️0
Smknf250 Smknf250 4 years ago
I don’t see any filing that reflects that. Where do you see it?
👍️0
make it happen make it happen 4 years ago
Director sold 725,000 shares @ $55.44 and 25,000 @ $45.83 total of 800,000 shares

Capitalization at it's finest, run for the hills. imho

bounce off 30's then into 20's
👍️0
make it happen make it happen 4 years ago
B. Wriley Price target $27.00. Price Per Share PPS is $47.00. Only $20.00 to drop to hit raised price target.
👍️0
make it happen make it happen 4 years ago
$1.40* opps

1-7 R/S

Sold drug in a few years will prob do another one sadly
👍️0
make it happen make it happen 4 years ago
Don't forget was like $1.10 at one point. Only 2 mil Revenue VS 2.7 expected.. while losing 56.4 mil in the second quarter or over 225,000,000 million loss for the year.

-$225,000,000 vs maybe 4 mil on a good year

Downgraded to under preform

Sold the drug now have nada

Also had nice size R/S in the past
👍️0
make it happen make it happen 4 years ago
Posted Revenue of $2 million vs estimated 2.7 mil.

Loss of $56.4 million second quarter only.

Huge differences

Sold the drug... No mo

Down graded to underperform
👍️0
make it happen make it happen 4 years ago
Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

Oh no...
👍️0
dinogreeves dinogreeves 4 years ago
ARCT the next NVAX.
👍️0
Cosa Cosa 4 years ago
might be getting squeezed, the float is so low.
👍️0
Cosa Cosa 4 years ago
wow this is pumping
👍️0
Atown62 Atown62 4 years ago
Thoughts now?
👍️0
Clemdane Clemdane 4 years ago
Still long here. This is a looong term buy. Disappointing that we got that massive haircut, but we've had them before and recovered. It's the nature of this volatile sector.
👍️0
Atown62 Atown62 4 years ago
Well?
👍️0
lecorb lecorb 4 years ago
In TDAmeritrade. TIPRANKS 7 SCROE PT: $88.25
Analyst Ratings, Moderate Buy! Last actualitation!
Based on the 10 sell-sidetooltipClick this button to read the definition of sell-side analysts who offered a 12-month price target in the last three months. Analysts predict a(n) 122.80% increase from today.
Kumaraguru Raja
Brookline Capital Markets
5Stars target $102.00rankingBuyanalystAction
Maintained date 2 days ago
analyst
Steven Seedhouse
Raymond James
5 Stars target ranking Hold analystAction Downgraded date 2 days ago
analyst
Yasmeen Rahimi
Piper Sandler
5Star target $140.00 ranking Buy analystAction Maintained
date 2 days ago
analyst
Seamus Fernandez
Guggenheim
5 Stars target -- ranking Buy analystAction Maintained date
2 days ago
Madhu Kumar
Robert W. Baird
5 Stars target $69.00 ranking Hold analystAction Downgraded
date
2 days ago
analyst
Elemer Piros
Roth Capital
5 Stars target $77.00 ranking Sell analystAction Maintained
date 2 days ago
Mayank Mamtani
B.Riley Financial
5 Stars target $138.00 ranking Buy analystAction Maintained
date 2 days ago
analyst
Yigal Nochomovitz
Citigroup
5Stars target $133.00 ranking Buy analystAction Maintained
date 17 days ago
👍️0
sanderburwil sanderburwil 4 years ago
Nope- was just a good “tax dump day” excuse today. Not holding- but really tempted- can only see upwards from here. Cathy woods didn’t sell a share today. Tells you something..
👍️0
Willymon Willymon 4 years ago
ARCT - Re-enter in the 30's. 34-37 seems to be my gate with this one.


The ol' "buy the rumor, sell the news" strikes again.


Or, today is last day to sell for 2020 taxes -- Dump day.


Take your pick.


It's a pandemic market and more crazy and unexpected things to come.


Remember, ARCT has a lot more to offer than just COVID solutions.


Their tech enables many other biotech companies delivery and replication methods.


ARCT has established a 52-wk high of $130.


Many think it will go past that.

👍️0
ClayTrader ClayTrader 4 years ago
* * $ARCT Video Chart 12-29-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
Clemdane Clemdane 4 years ago
Wish I had flipped it. Hindsight is 20/20.
👍️0
Willymon Willymon 4 years ago
ARCT - Me as well. Been in-n-out four times with profits every time.


When I talk to others they never heard of ARCT.


Ready for the next leg.
👍️0
Clemdane Clemdane 4 years ago
I'm still in - going to see where the ride takes me
👍️0
Willymon Willymon 4 years ago
ARCT - Still going but nobody on iHub seems aware.


Some on Stocktwits saying this is going to $500-700.


I get 10x plays often, but this is a big 10x for sure.
👍️0
whytestocks whytestocks 4 years ago
JUST IN: $ARCT Why Arcturus Therapeutics Stock Soared Today

Shares of Arcturus Therapeutics Holdings (NASDAQ: ARCT) were soaring 12.7% higher as of 3:28 p.m. EST on Tuesday. The big jump came after the clinical-stage biotech provided its third-quarter update following the market close on Monday. Investors were less interested in Arcturus' fi...

In case you are interested ARCT - Why Arcturus Therapeutics Stock Soared Today
👍️0
whytestocks whytestocks 4 years ago
Breaking News: $ARCT Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency

LUNAR® lipids undetectable in plasma 48 hours following drug administration ARCT-810 well tolerated at doses up to 0.3 mg/kg, 0.4 mg/kg cohort to be completed in Q4 Initial dosing of OTC-deficient patients at a U.S. clinical site expected in Q4 Arcturus ...

Find out more ARCT - Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
👍️0
Clemdane Clemdane 5 years ago
I'm more amazed that anyone posted on this board. But I agree on the breakout!
👍️0
Willymon Willymon 5 years ago
ARCT - In it to win it.
👍️0
Biggiee Biggiee 5 years ago
Breakout! Blue skies.
👍️0
Clemdane Clemdane 5 years ago
Wow! Someone posted on the ARCT board. Thank you very much. I like your chart. I will put my faith in Fibonacci!
👍️0
TFMG TFMG 5 years ago
$ARCT | #ArcturusTherapeutics Breakout Alert



Potential long above $63.00
Upside Fibonacci target zone $76.00


👍️0
Clemdane Clemdane 5 years ago
Hello silent ARCT board. Just a message to say I am still here! Still long ARCT.
👍️0
Clemdane Clemdane 5 years ago
That's what I thought. Thank you.
👍️0
Willymon Willymon 5 years ago
$ARCT - Doesn't look like the two are comparable.

$ARCT's self replicating delivery method along with the protein they are developing to block the keyholes in the host (humans) the spikes on viruses need to infect the host is a unique approach. Can't spike into a receiving host keyhole, no infection or replication. Game over.

$ARCT would be one shot as a cure for nearly all viruses, including the common flu.

I'm also a little weary with all these biotechs promising cures so soon.

Rhinovirus(Flu/common cold) still has no vaccine which they have been working to cure since the 1950's.

$ARCT thinks they have the total solution.

👍️0
Clemdane Clemdane 5 years ago
Hey do you know anywhere with a good competitive analysis of ARCT vs. the Oxford University vaccine?
👍️0
Clemdane Clemdane 5 years ago
It's truly incredible. I'm thrilled to be here.
👍️0
Willymon Willymon 5 years ago
$ARCT - News out today. How you feeling about those 13's now?
👍️0
pix pix 5 years ago
Shortly they hopefully will give some details to preclinical studies...
If positive, watch out...
👍️0
Willymon Willymon 5 years ago
$ARCT - Singapore has set and is setting the example to follow in all this.

The fact that they selected $ARCT to develop a cure is very telling.

Arcturus announced that it is partnering with Duke-NUS, a partnership between the Duke University School of Medicine and the National University of Singapore, to develop a COVID-19 vaccine to prevent infection by the coronavirus. The government of Singapore will pay for the vaccine's development -- $10 million to be paid part up-front, part upon achievement of unspecified "development milestones." And Singapore will get first dibs on any vaccines produced (plus potential royalties on vaccine sales outside of Singapore).Link>

👍️0
pix pix 5 years ago
If approved in Singapore, they will get access to many Asian countries....
👍️0
Clemdane Clemdane 5 years ago
Incredible. I have it in an IRA. Going to try to get more.
👍️0
Willymon Willymon 5 years ago
$ARCT - $13.90 is sooner. Nobody here is even aware of them. And, with only 1100 on stocktwits, nobody there is aware.

If you buy at $50 and it goes to $110, you're still in profit. But, now we're into the "What IF" game. Have to be long on $ARCT.

If they come up with the Covid-19 vaccine, then that also means they also cured thousands of other viruses.

Their method is to provide humans with a way to clog the keyholes that the spikes on viruses need to plug into to infect and replicate.

They don't patent some of their methods on purpose because a patent must show exactly how something works. This is to their advantage so other biotech companies have to go figure it out on their own. Trade secret.

👍️0

Your Recent History

NASDAQ
ARCT
Arcturus Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads